Cyclopharm logo

CYC - Cyclopharm Share Price

A$2.62 -0.0  -1.1%

Last Trade - 14/05/21

Small Cap
Market Cap £115.7m
Enterprise Value £117.3m
Revenue £8.08m
Position in Universe 608th / 1911
Unlock CYC Revenue
Relative Strength (%)
1m +1.34%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
12.6 14.4 13.3 13.5 14.1 14.7 18.6 +3.1%
+58.1 -74.7
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Cyclopharm Limited revenues increased 4% to A$14.7M. Netloss increased from A$2.9M to A$6M. Revenues reflectMolecular Imaging segment increase from A$2K to A$154K.Higher net loss reflects Employee benefits expense -Balancing va increase of 38% to A$7.1M (expense), Other NonRec I/E - Non Business Activ decrease from A$976K (income)to A$0K. Dividend per share remained flat at A$0.01.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CYC Revenue Unlock CYC Revenue

Net Income

CYC Net Income Unlock CYC Revenue

Normalised EPS

CYC Normalised EPS Unlock CYC Revenue

PE Ratio Range

CYC PE Ratio Range Unlock CYC Revenue

Dividend Yield Range

CYC Dividend Yield Range Unlock CYC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CYC EPS Forecasts Unlock CYC Revenue
Profile Summary

Cyclopharm Limited is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. The Company operates in two business segments: Technegas segment and Molecular imaging segment. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals used by physicians in the detection of cancer, neurological disorders and cardiac diseases. The Company offers Technegas for lung imaging, and Molecular Imaging/Positron Emission Tomography radiopharmaceuticals, which are used in cancer, brain and cardiac imaging. The Company formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Company's Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 31, 2005
Public Since January 18, 2007
No. of Shareholders: 1,288
No. of Employees: 48
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index S&P/ASX All Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 80,274,455
Free Float (0.0%)
Eligible for
CYC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CYC
Upcoming Events for CYC
Frequently Asked Questions for Cyclopharm
What is the Cyclopharm share price?

As of 14/05/21, shares in Cyclopharm are trading at A$2.62, giving the company a market capitalisation of £115.7m. This share price information is delayed by 15 minutes.

How has the Cyclopharm share price performed this year?

Shares in Cyclopharm are currently trading at A$2.62 and the price has moved by 92.65% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cyclopharm price has moved by 44.18% over the past year.

What are the analyst and broker recommendations for Cyclopharm?

Of the analysts with advisory recommendations for Cyclopharm, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cyclopharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cyclopharm next release its financial results?

Cyclopharm is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Cyclopharm dividend yield?

The Cyclopharm dividend yield is 0.38% based on the trailing twelve month period.

Does Cyclopharm pay a dividend?

Last year, Cyclopharm paid a total dividend of 0.01, and it currently has a trailing dividend yield of 0.38%. Looking ahead, Cyclopharm has not announced an ex-dividend date yet.

When does Cyclopharm next pay dividends?

Cyclopharm has yet to annouce their ex-dividend date. The historic dividend yield on Cyclopharm shares is currently 0.38%.

How do I buy Cyclopharm shares?

To buy shares in Cyclopharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cyclopharm?

Shares in Cyclopharm are currently trading at A$2.62, giving the company a market capitalisation of £115.7m.

Where are Cyclopharm shares listed? Where are Cyclopharm shares listed?

Here are the trading details for Cyclopharm:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CYC
What kind of share is Cyclopharm?

Based on an overall assessment of its quality, value and momentum, Cyclopharm is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cyclopharm share price forecast 2021?

Shares in Cyclopharm are currently priced at A$2.62. At that level they are trading at 44.54% discount to the analyst consensus target price of 0.00.

Analysts covering Cyclopharm currently have a consensus Earnings Per Share (EPS) forecast of -0.07 for the next financial year.

How can I tell whether the Cyclopharm share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyclopharm. Over the past six months, the relative strength of its shares against the market has been 18.05%. At the current price of A$2.62, shares in Cyclopharm are trading at 15.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cyclopharm PE Ratio?

We were not able to find PE ratio data for Cyclopharm.

Who are the key directors of Cyclopharm?

Cyclopharm's management team is headed by:

David Heaney - NEC
Graham Phillips - OTH
Lynn McLauchlin - GMG
James McBrayer - MDR
Caryn Cheah - CTR
Tom McDonald - NID
Mark Doverty - OTH
Niamh McAree - OTH
Sally-Ann Cornelius - OTH
Chris Quinn - OTH
Mathew Farag - COO
Who are the major shareholders of Cyclopharm?

Here are the top five shareholders of Cyclopharm based on the size of their shareholding:

Anglo Australian Christian and Charitable Fund Corporation
Percentage owned: 14.15% (13.2m shares)
Barings Acceptance Ltd. Corporation
Percentage owned: 12.26% (11.4m shares)
Australian Ethical Investment Ltd. Investment Advisor
Percentage owned: 9.87% (9.22m shares)
Chemical Investments Ltd Corporation
Percentage owned: 9.84% (9.19m shares)
Karst Peak Capital Limited Hedge Fund
Percentage owned: 9.54% (8.91m shares)
Similar to CYC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.